



KEY:		Please note the program takes place in CET - Central European Time Gothenburg (Sweden)				
PRE CONFERENCE SYMPOSIUM	SPONSORED SYMPOSIUM	SYMPOSIUM	PLENARY LECTURE	FORUM	OTHER EVENT	
Please note that On-Demand Sessions are listed at the end of this program.						
Tuesday, March 28, 2023						
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite - Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	
08:00 - 15:50		PUBLIC EVENT - ADPD PRESENTS NEW TIMES IN ALZHEIMER'S DISEASE: FROM PREVENTION TO THERAPY (14:00 - 15:00)	PRE CONFERENCE SYMPOSIUM (09:00 - 13:00)	PRE CONFERENCE SYMPOSIUM - COMMON FEATURES OF NEURODEGENERATIVE DISEASES: EXPLORING THE BRAIN/EYE CONNECTION AND BEYOND : USE IT OR LOSE IT: HOW TINY CHANGES IN ENERGY, METABOLISM AND MITOCHONDRIA CAN LEAD TO NEURODEGENERATIVE DISEASE	PRE CONFERENCE SYMPOSIUM	
17:00 -17:50	OPENING CEREMONY AND AWARDS					
17:50 - 18:00	BREAK					
18:00 -19:10	PLENARY LECTURE 1, 2 and 3					
WELCOME RECEPTION IN EXHIBITION						



Wednesday, March 29, 2023						
	On-Demand Oral					
07:00 - 08:30	On-demand symposia					
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite - Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	Onsite - Hall G2 (No Live Stream; On-Demand Gallery of Virtual Platform)
08:30 - 09:00	PLENARY LECTURE 4					
09:00 - 09:10	BREAK					
09:10 - 11:10	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	CELLULAR MECHANISMS OF VULNERABILITY AND ABETA TOXICITY	GENETICS OF NEURODEGENERATION 1	APOE: MECHANISMS AND TREATMENT STRATEGIES	BIOMARKER MODULATORS: KIDNEY FUNCTION, ETHNICITY, AND GENDER	α--SYNUCLEIN, PATHOPHYSIOLOGY: AGGREGATION AND SEEDING
11:10 - 11:40	EXHIBITION, POSTERS AND COFFEE BREAK					
11:40 - 13:25	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
13:25 - 14:45	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS					
14:45 - 16:45	FORUM 1: BLOOD-BASED BIOMARKERS COMPARISON TO CSF AND IMAGING BIOMARKERS. ASSESSMENT FOR DIAGNOSES & TREATMENT EFFECTS: HOW TO MEASURE MINIMAL CLINICAL EFFICACY? (14:45 - 15:45)	MICROGLIA. TREM2, NEUROINFLAMMATION 1	AD THERAPY: TARGETING TAU	TRANSLATIONAL DRUG DISCOVERY: THE VALUE OF ANIMAL MODELS AND ORGANOIDS	TARGETING NLRP3 AND NEUROINFLAMMATION IN AD AND PD	GENETICS OF NEURODEGENERATION 2
	FORUM 2: IMMUNOTHERAPIES IN AD: FROM BASICS TO APPROVAL (15:55 - 16:55)					
16:50 - 17:20	EXHIBITION, POSTERS AND COFFEE BREAK					
17:20 - 19:20	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	FLUID BIOMARKERS AND IMAGING IN PD AND LBD	TDP43-, PROGRANULIN-, AND C9ORF72- RELATED DISEASES	CELL REPLACEMENT THERAPY: IPSC, GLIA AND GRAFTS	GLIAL CELLS AND MECHANISMS OF NEURODEGENERATION	SELECTIVE VULNERABILITY, GLIAL CELLS AND MECHANISMS OF NEURODEGENERATION



Thursday, March 30, 2023						
	On-Demand Oral					
07:00 - 08:30	On-demand symposia					
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite - Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	Onsite - Hall G2 (No Live Stream; On-Demand Gallery of Virtual Platform)
08:00 - 08:30	PLENARY LECTURE 5					
08:30 - 08:40	BREAK					
08:40 - 10:40	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	CEREBRAL CONSEQUENCES OF VASCULAR CHANGES	ALPHA-SYNUCLEIN PATHOGENESIS, DETECTION & TREATMENT STRATEGIES	LIPID DYSHOMEOSTASIS IN NEUROGENERATIVE DISEASES	SYNAPTIC HOMEOSTASIS AND DYSFUNCTION, NEURONAL NETWORKS	TDP43- AND C9ORF72-RELATED DISEASES
10:40 - 11:10	EXHIBITION, POSTERS AND COFFEE BREAK					
11:10-12:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
12:50- 13:50	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS					
13:50-15:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (13:50 - 14:50)	ABETA TARGETING THERAPIES IN AD 1	MRI 1	FTD, ALS: TDP-43 , C9ORF72 AND TMEM106B	MITOCHONDRIA, AUTOPHAGY, MITOPHAGY IN AD, PD	FLUID BIOMARKERS 1
	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (15:00 - 16:00)					
15:50-16:20	EXHIBITION, POSTERS AND COFFEE BREAK					
16:20 - 18:20	FORUM 3: PHASE I-III IN AD: DRUG DEVELOPMENT AND RELEVANCE FOR HETEROGENEITY OF THE DISEASE (16:20- 17:20)	DEMENTIA PREVENTION STRATEGIES; VALIDATING BIOMARKERS	APOE MECHANISMS AND TREATMENT STRATEGIES	FTD, ALS: C9ORF72, TDP-43	EXOSOMES	TAU PATHOLOGY 1
	FORUM 4: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING AND THERAPY OF ALPHA-SYNUCLEIN, LRRK2, GBA PATHOLOGIES (17:25 - 18:25)					
18:25 -18:35	BREAK					
18:35 - 19:35	AD DRUG DEVELOPMENT CLINICAL TRIALS	ABETA & TAU TARGETING THERAPIES	PLASMA BIOMARKERS	FLUID BIOMARKERS, IMAGING	ASTROGLIA	TAU PATHOLOGY 2



Friday, March 31, 2023						
	On-Demand Oral					
07:00 - 08:30	6 On-demand symposia					
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite - Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	Onsite - Hall G2 (No Live Stream; On-Demand Gallery of Virtual Platform)
08:00 - 08:30	PLENARY LECTURE 6					
08:30 - 08:40	BREAK					
08:40 - 10:40	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	HETEROGENEITY AND SIMILARITIES IN THE NEUROPATHOLOGIES OF LBD, PD, FAD, DOWN SYNDROME AND AD	MICROGLIA. TREM2, NEUROINFLAMMATION 2	CHOLINERGIC MECHANISMS IN AD AND PD	BRAIN GUT INTERACTIONS MICROBIOME 1	EXPLORING NEW TARGETS IN AD, FTD, PD AND LBD
10:40 - 11:10	EXHIBITION, POSTERS AND COFFEE BREAK					
11:10 - 12:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
12:50 - 13:50	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS					
13:50 - 15:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	ABETA TARGETING THERAPIES IN AD 2	FLUID BIOMARKERS AND IMAGING IN MCI, AD	NEUROPATHOLOGIES OF LBD, PD, ALS, FAD, AND AD	TAU AND SYNUCLEIN TOXICITIES AND CELLULAR INTERACTIONS	ANIMAL MODELS, ORGANOIDs, SINGLE CELLS, IMAGING
15:50 - 16:20	EXHIBITION, POSTERS AND COFFEE BREAK					
16:20 - 18:30	FORUM 5: ANTI-TAU THERAPIES IN CLINICAL TRIALS (16:20 - 17:20)	CLINICAL TRIAL DESIGNS	SEX, GENDER, SIMILARITIES AND DIFFERENCES IN BIOMARKERS & PATHOPHYSIOLOGY	BLOOD BIOMARKERS	ALPHA-SYNUCLEIN, PD MECHANISTIC ASPECTS	SELECTIVE VULNERABILITY, PATHOPHYSIOLOGY, PATHOGENESIS IN AD, PD 1
	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (17:30 - 18:30)					
18:30 - 18:40	BREAK					
18:40 - 19:40	NEUROPATHOLOGIES OF LBD, PD, ALS, FAD, AND AD	TAU AND SYNUCLEIN TOXICITIES AND CELLULAR INTERACTIONS	FLUID BIOMARKERS AND IMAGING IN MCI, AD	ANIMAL MODELS, ORGANOIDs, SINGLE CELLS, STEM CELLS, IMAGING	EEG AND OTHER ASSESSMENT TOOLS	SELECTIVE VULNERABILITY, PATHOPHYSIOLOGY, PATHOGENESIS IN AD, PD 2



Saturday, April 1, 2023						
	On-Demand Oral					
07:00 - 08:30	6 On-demand symposia					
	Onsite - Hall C (Live Stream)	Onsite - Hall F1+F2+F3 (Live Stream)	Onsite - Hall F4+F5 (Live Stream)	Onsite - Hall G3 (Live Stream)	Onsite - Hall G4 (No Live Stream; On-Demand Gallery of Virtual Platform)	Onsite - Hall G2 (No Live Stream; On-Demand Gallery of Virtual Platform)
08:00 - 08:30	PLENARY LECTURE 7					
08:30 - 08:40	BREAK					
08:40 - 10:40	HOW SHOULD WE USE FLUID AND IMAGING BIOMARKERS IN CLINICAL PRACTICE?	AD & FAD THERAPEUTIC STRATEGIES	THE VULNERABLE BRAIN AND DEGENERATIVE MECHANISMS IN AD, PD AND TRAUMATIC BRAIN INJURY	PET 1	TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS IN AD, PD AND LBD DRUG DEVELOPMENT	GENETICS OF NEURODEGENERATION 3
10:40 - 11:10	EXHIBITION, POSTERS AND COFFEE BREAK					
11:10 - 13:10	TAUPATHIES: PATHOGENIC MECHANISMS	FLUID BIOMARKERS 2	EXPLORING NEW TARGETS IN AD, PD AND LBD	PET 2	THE POTENTIAL ROLE OF ASTROCYTES, MICROGLIA IN NEURODEGENERATION	α-SYNUCLEINOPATHIES: DISEASE MECHANISMS, PATHOPHYSIOLOGY: MODELING OF DISEASE PROGRESSION
13:10 - 14:45	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS					
14:45 - 16:45	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (14:45 - 15:45)	ADVANCES IN PD AND LBD DIAGNOSIS AND DRUG DEVELOPMENT	COVID-19 IMPACT ON NEURODEGENERATIVE DISEASES	FLUID BIOMARKERS AND IMAGING IN AD, PD AND PSP	TREM2, MICROGLIA, ASTROCYTES	EEG, SLEEP AND OTHER ASSESSMENT TOOLS
	FORUM 6: DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TOWARDS APPROVAL (15:55 - 16:55)					
16:55 - 17:25	EXHIBITION, POSTERS AND COFFEE BREAK					
17:25 - 19:25	DIAGNOSTIC ACCURACY, IMAGING AND FLUID BIOMARKERS AND IMAGING IN AD, FTD, PD, LBD	BACE-1, PRESENILIN, GAMMA-SECRETASE, TACE, APP, Abeta TRUNCATION, TOXICITY	SOC DRUGS AND OTHER TARGETED THERAPIES IN AD (CLINICAL TRIALS)	DRUG DEVELOPMENT IN AD, PD, LBD	AD, PD, LBD, BIOMARKERS, DIAGNOSIS, IMAGING & CLINICAL TRIALS	PSYCHIATRIC MANIFESTATIONS AND CORRELATES IN AD, PD AND LBD
19:25 - 19:35	CLOSING CEREMONY					

<b>Wednesday, March 29, 2023</b>
GENETICS OF NEURODEGENERATION 4
GENETICS OF NEURODEGENERATION 5
VULNERABILITY AND RISK FACTORS, PROGRESSION NEURODEGENERATION AND PATHOLOGY
VULNERABILITY AND RISK FACTORS, HETEROGENEITY. PROGRESSION NEURODEGENERATION AND PATHOLOGY
DIGITAL AND CLOUD BASED TOOLS, AI, MACHINE LEARNING
NLRP3 INFLAMMASOME, NEUROINFLAMMATION, TREM2, MICROGLIA DYSFUNCTION
DIGITAL HEALTH TECHNOLOGIES, MACHINE LEARNING
<b>Thursday, March 30, 2023</b>
TAU PATHOLOGY
FLUID BIOMARKERS AND IMAGING IN AD, PD AND LBD
FLUID BIOMARKERS 3
FLUID BIOMARKERS 4
PET 3
MCI, AD & FAD THERAPEUTIC STRATEGIES
BACE-1, BACE-2, PRESENILIN, GAMMA-SECRETASE, TACE, APP
CEREBRAL CONSEQUENCES OF VASCULAR CHANGES
<b>Friday, March 31, 2023</b>
$\alpha$ -SYNUCLEINOPATHIES: ALPHA-SYNUCLEIN PATHOGENESIS, DOPAMINE, LRRK2, PATHOPHYSIOLOGY
$\alpha$ -SYNUCLEINOPATHIES: ALPHA-SYNUCLEIN PATHOGENESIS, DOPAMINE, ANIMAL MODELS, ORGANIDS
THERAPEUTIC TARGETS IN PD AND LBD: PRECLINICAL AND CLINICAL DRUG DEVELOPMENT
MITOCHONDRIAL DYSFUNCTION, AUTOPHAGY, MITOPHAGY IN AD, PD
BRAIN GUT INTERACTIONS – MICROBIOME 2

AD, MCI, PD- PSYCHIATRIC & NEUROPHYSIOLOGICAL MANIFESTATIONS. ECONOMIC STATUS, CARE & SUPPORT
A-BETA TOXICITY
THERAPEUTIC TARGETS IN AD: PRECLINICAL STUDIES
<b>Saturday , April 1, 2023</b>
TDP43- AND C9ORF72-RELATED DISEASES
DISEASE MECHANISMS, PATHOPHYSIOLOGY: ASTROCYTES, MICROGLIA, IMMUNE PROTECTION, NEUROINFLAMMATION
CLINICAL TRIALS DESIGN, DIAGNOSTIC CRITERIA
CLINICAL AND NEUROPATHOLOGICAL FEATURES ACROSS MULTIPLE
IPSC, STEM CELLS, CELL REPLACEMENT THERAPY
MRI 2
A-BETA & TAU TARGETING THERAPIES IN AD AND DISEASE MODIFYING THERAPIES
ANIMAL MODELS FOR AD

